Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
afamitresgene, anaemia, APCT, arrhythmia, ATM, autoleucel, break, cava, CEO, championed, chart, Cintia, circumvent, claimable, condensed, confusional, contractor, contrast, Cowen, creatinine, cut, deep, deficiency, deficient, EEA, embolism, empyema, eosinophilia, franchise, gen, GNE, headcount, HSR, inconsistency, injunction, intestinal, joined, lymphoproliferative, membership, neutrophil, occlusion, ORR, Piccina, platelet, pneumothorax, provisionally, pulmonary, referenda, retiring, Roche, slightly, solvency, symbol, TCA, thirteen, transposed, undermine, underpayment, vein, vena, wholesale
Removed:
adjusting, Africa, amounted, atrial, bill, capitalizing, China, Cloud, codified, comparative, Computing, cure, diarrhea, easily, eighteen, exit, falling, febrile, fibrillation, France, funded, gammadelta, geographic, Germany, goal, half, headache, hepatocellular, holiday, hosting, individually, inducible, infrequently, Italy, landlord, leasehold, Matrix, Norway, notified, NSCLC, opted, permitting, processed, retrospectively, scheduled, shorter, South, Spain, summarized, Syncona, unresponsive, unusual, urothelial, yearly
Filing tables
Filing exhibits
Associated ADAP transcripts
ADAP similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Adaptimmune Therapeutics plc:
We consent to the incorporation by reference in the registration statements Nos. 333-233557 and 333-243743 on Form S-3 and Nos. 333-233558 and 333-203929 on Form S-8 of Adaptimmune Therapeutics plc of our reports dated March 14, 2022, with respect to the consolidated financial statements of Adaptimmune Therapeutics plc and the effectiveness of internal control over financial reporting.
/s/ KPMG LLP
Reading, United Kingdom
March 14, 2022